Skip to main content
padlock icon - secure page this page is secure

Open Access Development of Disease-Modifying Therapeutics in Alzheimer's disease and Dementia with Lewy Body (DLB)

Download Article:
 Download
(PDF 202.3 kb)
 
Neurodegenerative diseases are a growing problem as our lifespans continue to increase, such that Alzheimer's disease and other forms of dementia represent a major cause of disability and death worldwide. Researchers are working to unravel the brain chemistry that leads to these diseases of old age and to develop therapies to slow cognitive decline. Professor Kohji Fukunaga and his team have been working in this field for many years. He says: 'We are now on the brink of introducing a novel drug that has been shown to improve memory and learning faculties in mice models of Alzheimer's disease (AD).' Fukunaga is lead researcher at the Department of Pharmacology in the Tohoku University Graduate School of Pharmaceutical Sciences in Japan, and heads up the current project stream of AMED for the development of disease-modifying therapeutics for Alzheimer's disease, Parkinson's disease and dementia with Lewy Bodies. A target molecular pathway was identified in 2013, and was optimised during the following year. The Japanese Agency for Medical Research thereafter funded preclinical research focusing on synthesis techniques, toxicology, pharmacokinetic and pharmacodynamic studies. The new compound is called SAK3 and has demonstrated cognitive enhancement superior to that of existing drugs currently used to slow the onset of AD on transgenic mice. Exhaustive safety trials have also been undertaken on larger animal models. The team is now seeking funding and pharmaceutical partners for human clinical trials, with a view to licensing and eventual commercialisation over the next five years.

SAK3 has been tested on two different mouse models of AD: olfactory bulbectomised, APP23 and APP knock-in. The first display cognitive impairment and depressive behaviours, while the latter have a seven-fold increase in a mutant form of amyloid beta precursor proteins in their synapses. Both exhibit elevated levels of Abeta production in the brain. Fukunaga says: 'Two months after administering our SAK3 compound to APP23 or APP knock-in mice, we observed reduced Abeta accumulations. Also, we used a novel object recognition task to assess cognitive performance and found a significant improvement.' SAK3's effects were compared to those of existing ACh release and stimulation agents ST101 and Donepezil, and shown to be significantly superior. These drugs are both produced by Fukunaga's long-term US collaborators, Sonexa Therapeutics Inc.
No References for this article.
No Supplementary Data.
No Article Media
No Metrics

Keywords: ALZHEIMER'S DISEASE; COGNITIVE ENHANCEMENT; DEMENTIA; DEMENTIA WITH LEWY BODIES; DISEASE-MODIFYING THERAPEUTICS FOR ALZHEIMER'S DISEASE; NEURODEGENERATIVE DISEASE; PARKINSON'S DISEASE; PHARMACOKINETIC AND PHARMACODYNAMIC STUDIES; SAK3; TOXICOLOGY

Document Type: Research Article

Publication date: October 15, 2018

More about this publication?
  • Impact is a series of high-quality, open access and free to access science reports designed to enable the dissemination of research impact to key stakeholders. Communicating the impact and relevance of research projects across a large number of subjects in a content format that is easily accessible by an academic and stakeholder audience. The publication features content from the world's leading research councils, policy groups, universities and research projects. Impact is published under a CC-BY Creative Commons licence.

  • Subscribe to this Title
  • Terms & Conditions
  • Disseminating research in Impact
  • Information about Impact
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more